← Back to Clinical Trials
Recruiting NCT06061185

NCT06061185 Multimodal Computed Tomography in Patients With Acute Hemorrhagic Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06061185
Status Recruiting
Phase
Sponsor Xiaolin Chen, MD
Condition Acute Hemorrhagic Stroke
Study Type OBSERVATIONAL
Enrollment 10,000 participants
Start Date 2020-01-01
Primary Completion 2032-03-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type OBSERVATIONAL
Interventions
Multimodal CT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 10,000 participants in total. It began in 2020-01-01 with a primary completion date of 2032-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Acute hemorrhagic stroke is a series of neurosurgical diseases characterized by bleeding with high morbidity and mortality. It accounts for about 20% of all strokes worldwide and mainly includes subtypes such as intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH). Multimodal computed tomography including non-contrast computed tomography, computed tomography angiography and computed tomography perfusion, is of great important in understanding pathophysiological changes, evaluating prognosis and guiding interventions in these diseases.

Eligibility Criteria

Inclusion Criteria: 1. age ≥ 18, ≤ 85 years; 2. presence with hemorrhagic stroke Exclusion Criteria: 1. with a history of previous history of ischemic/hemorrhagic stroke; 2. admission to the emergency department more than a week after symptom onset; 3. serious medical history or existing comorbidities; 4. physical disability due to previous diseases; 5. prior treatment such as external ventricular drainage, digital subtraction angiography and lumbar puncture in other institution; 6. poor original image quality; 7. incomplete follow-up.

Contact & Investigator

Central Contact

Xiaolin Chen, M.D.

✉ chenxiaolin@bjtth.org

📞 13810624845

Principal Investigator

Tu Li, M.D.

STUDY CHAIR

Beijing Tiantan Hospital

Frequently Asked Questions

Who can join the NCT06061185 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Acute Hemorrhagic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06061185 currently recruiting?

Yes, NCT06061185 is actively recruiting participants. Contact the research team at chenxiaolin@bjtth.org for enrollment information.

Where is the NCT06061185 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT06061185 clinical trial?

NCT06061185 is sponsored by Xiaolin Chen, MD. The principal investigator is Tu Li, M.D. at Beijing Tiantan Hospital. The trial plans to enroll 10,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology